+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Head & Neck Cancer Drugs Market Research Report by Drug Class, Product, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 256 Pages
  • October 2022
  • Region: Global
  • 360iResearch™
  • ID: 5454865
UP TO OFF until Dec 31st 2022
The Global Head & Neck Cancer Drugs Market size was estimated at USD 1,021.86 million in 2021, USD 1,176.67 million in 2022, and is projected to grow at a CAGR of 15.32% to reach USD 2,404.25 million by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Head & Neck Cancer Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Class, the market was studied across Chemotherapy, Immunotherapy, Radiation therapy, Surgery, and Targeted Therapy.
  • Based on Product, the market was studied across Bleomycin, Cetuximab, Docetaxel, Erbitux (Cetuximab), Hydrea (Hydroxyurea), Hydroxyurea, Keytruda (Pembrolizumab), Methotrexate, Nivolumab, Opdivo (Nivolumab), Pembrolizumab, Taxotere (Docetaxel), and Trexall (Methotrexate).
  • Based on End User, the market was studied across Cancer Research Institutes, Clinics, and Hospitals.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. The ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

The publisher continuously monitors and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Head & Neck Cancer Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Head & Neck Cancer Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Head & Neck Cancer Drugs Market, including AbbVie, Amgen Inc., AstraZeneca Plc., BeiGene, Biocon, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company Limited, F. Hoffmann-La Roche Ltd., Fortress Biotech, Inc., Fresenius Medical Care AG & Co. KGaA, Gilead Sciences, GlaxoSmithKline, Incyte Corp, Johnson & Johnson, Merck & Co., Inc., NEC Corporation, North Carolina Biotechnology Center, Novartis, Pfizer Inc., Roche Holding AG, Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Head & Neck Cancer Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Head & Neck Cancer Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Head & Neck Cancer Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Head & Neck Cancer Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Head & Neck Cancer Drugs Market?
6. What is the market share of the leading vendors in the Global Head & Neck Cancer Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Head & Neck Cancer Drugs Market?
Frequently Asked Questions about the Global Head & Neck Cancer Drugs Market

What is the estimated value of the Global Head & Neck Cancer Drugs Market?

The Global Head & Neck Cancer Drugs Market was estimated to be valued at $1021.86 Million in 2021.

What is the growth rate of the Global Head & Neck Cancer Drugs Market?

The growth rate of the Global Head & Neck Cancer Drugs Market is 15.3%, with an estimated value of $2404.25 Million by 2027.

What is the forecasted size of the Global Head & Neck Cancer Drugs Market?

The Global Head & Neck Cancer Drugs Market is estimated to be worth $2404.25 Million by 2027.

Who are the key companies in the Global Head & Neck Cancer Drugs Market?

Key companies in the Global Head & Neck Cancer Drugs Market include AbbVie, Amgen Inc., AstraZeneca Plc., BeiGene, Biocon, Bristol, Myers Squibb Company, Celgene Corporation and F. Hoffmann.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of head and neck cancer all across the globe
5.1.1.2. Growing consumption of smoking and drinking addictions
5.1.2. Restraints
5.1.2.1. High cost of the drugs
5.1.3. Opportunities
5.1.3.1. Potential growth opportunity in the emerging countries
5.1.3.2. Active presence of late-stage pipeline drugs
5.1.4. Challenges
5.1.4.1. Adverse effect associated with the consumption of the drug
5.2. Cumulative Impact of COVID-19
6. Head & Neck Cancer Drugs Market, by Drug Class
6.1. Introduction
6.2. Chemotherapy
6.3. Immunotherapy
6.4. Radiation therapy
6.5. Surgery
6.6. Targeted Therapy
7. Head & Neck Cancer Drugs Market, by Product
7.1. Introduction
7.2. Bleomycin
7.3. Cetuximab
7.4. Docetaxel
7.5. Erbitux (Cetuximab)
7.6. Hydrea (Hydroxyurea)
7.7. Hydroxyurea
7.8. Keytruda (Pembrolizumab)
7.9. Methotrexate
7.10. Nivolumab
7.11. Opdivo (Nivolumab)
7.12. Pembrolizumab
7.13. Taxotere (Docetaxel)
7.14. Trexall (Methotrexate)
8. Head & Neck Cancer Drugs Market, by End User
8.1. Introduction
8.2. Cancer Research Institutes
8.3. Clinics
8.4. Hospitals
9. Americas Head & Neck Cancer Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Head & Neck Cancer Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Head & Neck Cancer Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AbbVie
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Amgen Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. AstraZeneca Plc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. BeiGene
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Biocon
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Bristol-Myers Squibb Company
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Celgene Corporation
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Eli Lilly and Company Limited
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. F. Hoffmann-La Roche Ltd.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Fortress Biotech, Inc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Fresenius Medical Care AG & Co. KGaA
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Gilead Sciences
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. GlaxoSmithKline
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Incyte Corp
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Johnson & Johnson
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Merck & Co., Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. NEC Corporation
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. North Carolina Biotechnology Center
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Novartis
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Pfizer Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Roche Holding AG
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Sanofi
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Sun Pharmaceutical Industries Ltd.
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Takeda Pharmaceutical Company Limited
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Teva Pharmaceutical Industries Limited
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL HEAD & NECK CANCER DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, 2021 VS 2027
FIGURE 3. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 4. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 6. GLOBAL HEAD & NECK CANCER DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2027
FIGURE 7. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 8. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 9. GLOBAL HEAD & NECK CANCER DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 10. GLOBAL HEAD & NECK CANCER DRUGS MARKET DYNAMICS
FIGURE 11. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (%)
FIGURE 12. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL HEAD & NECK CANCER DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY DRUG CLASS, 2027
FIGURE 14. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2027 (USD MILLION)
FIGURE 15. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2027 (USD MILLION)
FIGURE 16. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, 2018-2027 (USD MILLION)
FIGURE 17. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SURGERY, 2018-2027 (USD MILLION)
FIGURE 18. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2027 (USD MILLION)
FIGURE 19. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2021 VS 2027 (%)
FIGURE 20. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2021 VS 2027 (USD MILLION)
FIGURE 21. GLOBAL HEAD & NECK CANCER DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY PRODUCT, 2027
FIGURE 22. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY BLEOMYCIN, 2018-2027 (USD MILLION)
FIGURE 23. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CETUXIMAB, 2018-2027 (USD MILLION)
FIGURE 24. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DOCETAXEL, 2018-2027 (USD MILLION)
FIGURE 25. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ERBITUX (CETUXIMAB), 2018-2027 (USD MILLION)
FIGURE 26. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDREA (HYDROXYUREA), 2018-2027 (USD MILLION)
FIGURE 27. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDROXYUREA, 2018-2027 (USD MILLION)
FIGURE 28. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY KEYTRUDA (PEMBROLIZUMAB), 2018-2027 (USD MILLION)
FIGURE 29. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY METHOTREXATE, 2018-2027 (USD MILLION)
FIGURE 30. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, 2018-2027 (USD MILLION)
FIGURE 31. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY OPDIVO (NIVOLUMAB), 2018-2027 (USD MILLION)
FIGURE 32. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, 2018-2027 (USD MILLION)
FIGURE 33. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TAXOTERE (DOCETAXEL), 2018-2027 (USD MILLION)
FIGURE 34. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TREXALL (METHOTREXATE), 2018-2027 (USD MILLION)
FIGURE 35. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2021 VS 2027 (%)
FIGURE 36. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2021 VS 2027 (USD MILLION)
FIGURE 37. GLOBAL HEAD & NECK CANCER DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY END USER, 2027
FIGURE 38. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, 2018-2027 (USD MILLION)
FIGURE 39. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2027 (USD MILLION)
FIGURE 40. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2027 (USD MILLION)
FIGURE 41. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 42. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 43. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 44. AMERICAS HEAD & NECK CANCER DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 45. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 46. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 47. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 48. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 49. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 50. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 51. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 52. UNITED STATES HEAD & NECK CANCER DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 53. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 54. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 55. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 56. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 57. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 58. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 59. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 60. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 61. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 62. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 63. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 64. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 65. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 66. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 67. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 68. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 69. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 70. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 71. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 72. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 73. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 74. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 75. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 76. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 77. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 78. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 79. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 80. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 81. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 82. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 83. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 84. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 85. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 86. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 87. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 88. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 89. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 90. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 91. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 92. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 93. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 94. GLOBAL HEAD & NECK CANCER DRUGS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 95. GLOBAL HEAD & NECK CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 96. GLOBAL HEAD & NECK CANCER DRUGS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. GLOBAL HEAD & NECK CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2021
TABLE 3. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 4. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY REGION, 2018-2027 (USD MILLION)
TABLE 5. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 6. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 7. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2027 (USD MILLION)
TABLE 8. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 9. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 10. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2027 (USD MILLION)
TABLE 11. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 12. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 13. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, 2018-2027 (USD MILLION)
TABLE 14. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 15. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 16. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SURGERY, 2018-2027 (USD MILLION)
TABLE 17. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2027 (USD MILLION)
TABLE 18. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2027 (USD MILLION)
TABLE 19. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2027 (USD MILLION)
TABLE 20. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 21. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 22. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 23. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY BLEOMYCIN, 2018-2027 (USD MILLION)
TABLE 24. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY BLEOMYCIN, BY REGION, 2018-2027 (USD MILLION)
TABLE 25. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY BLEOMYCIN, BY REGION, 2018-2027 (USD MILLION)
TABLE 26. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CETUXIMAB, 2018-2027 (USD MILLION)
TABLE 27. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CETUXIMAB, BY REGION, 2018-2027 (USD MILLION)
TABLE 28. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CETUXIMAB, BY REGION, 2018-2027 (USD MILLION)
TABLE 29. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DOCETAXEL, 2018-2027 (USD MILLION)
TABLE 30. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DOCETAXEL, BY REGION, 2018-2027 (USD MILLION)
TABLE 31. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DOCETAXEL, BY REGION, 2018-2027 (USD MILLION)
TABLE 32. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ERBITUX (CETUXIMAB), 2018-2027 (USD MILLION)
TABLE 33. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ERBITUX (CETUXIMAB), BY REGION, 2018-2027 (USD MILLION)
TABLE 34. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ERBITUX (CETUXIMAB), BY REGION, 2018-2027 (USD MILLION)
TABLE 35. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDREA (HYDROXYUREA), 2018-2027 (USD MILLION)
TABLE 36. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDREA (HYDROXYUREA), BY REGION, 2018-2027 (USD MILLION)
TABLE 37. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDREA (HYDROXYUREA), BY REGION, 2018-2027 (USD MILLION)
TABLE 38. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDROXYUREA, 2018-2027 (USD MILLION)
TABLE 39. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDROXYUREA, BY REGION, 2018-2027 (USD MILLION)
TABLE 40. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDROXYUREA, BY REGION, 2018-2027 (USD MILLION)
TABLE 41. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY KEYTRUDA (PEMBROLIZUMAB), 2018-2027 (USD MILLION)
TABLE 42. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY KEYTRUDA (PEMBROLIZUMAB), BY REGION, 2018-2027 (USD MILLION)
TABLE 43. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY KEYTRUDA (PEMBROLIZUMAB), BY REGION, 2018-2027 (USD MILLION)
TABLE 44. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY METHOTREXATE, 2018-2027 (USD MILLION)
TABLE 45. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2027 (USD MILLION)
TABLE 46. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2027 (USD MILLION)
TABLE 47. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, 2018-2027 (USD MILLION)
TABLE 48. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2027 (USD MILLION)
TABLE 49. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2027 (USD MILLION)
TABLE 50. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY OPDIVO (NIVOLUMAB), 2018-2027 (USD MILLION)
TABLE 51. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY OPDIVO (NIVOLUMAB), BY REGION, 2018-2027 (USD MILLION)
TABLE 52. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY OPDIVO (NIVOLUMAB), BY REGION, 2018-2027 (USD MILLION)
TABLE 53. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, 2018-2027 (USD MILLION)
TABLE 54. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2027 (USD MILLION)
TABLE 55. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2027 (USD MILLION)
TABLE 56. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TAXOTERE (DOCETAXEL), 2018-2027 (USD MILLION)
TABLE 57. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TAXOTERE (DOCETAXEL), BY REGION, 2018-2027 (USD MILLION)
TABLE 58. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TAXOTERE (DOCETAXEL), BY REGION, 2018-2027 (USD MILLION)
TABLE 59. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TREXALL (METHOTREXATE), 2018-2027 (USD MILLION)
TABLE 60. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TREXALL (METHOTREXATE), BY REGION, 2018-2027 (USD MILLION)
TABLE 61. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TREXALL (METHOTREXATE), BY REGION, 2018-2027 (USD MILLION)
TABLE 62. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 63. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, 2018-2027 (USD MILLION)
TABLE 64. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2027 (USD MILLION)
TABLE 65. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2027 (USD MILLION)
TABLE 66. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2027 (USD MILLION)
TABLE 67. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2027 (USD MILLION)
TABLE 68. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2027 (USD MILLION)
TABLE 69. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2027 (USD MILLION)
TABLE 70. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2027 (USD MILLION)
TABLE 71. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2027 (USD MILLION)
TABLE 72. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 73. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 74. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 75. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 76. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 77. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 78. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 79. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 80. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 81. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 82. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 83. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 84. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 85. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 86. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 87. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 88. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 89. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 90. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 91. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 92. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 93. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 94. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2018-2027 (USD MILLION)
TABLE 95. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 96. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 97. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 98. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 99. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 100. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 101. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 102. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 103. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 104. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 105. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 106. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 107. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 108. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 109. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 110. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 111. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 112. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 113. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 114. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 115. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 116. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 117. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 118. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 119. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 120. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 121. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 122. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 123. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 124. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 125. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 126. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 127. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 128. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 129. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 130. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 131. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 132. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 133. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 134. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 135. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 136. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 137. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 138. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 139. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 140. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 141. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 142. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 143. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 144. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 145. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 146. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 147. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 148. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 149. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 150. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 156. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 157. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 158. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 159. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 160. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 161. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 162. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 163. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 164. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 165. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 166. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 167. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 168. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 169. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 170. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 171. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 172. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 173. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 174. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 175. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 176. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 177. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 178. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 179. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 180. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 181. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 182. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 183. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 184. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 185. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 186. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 187. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 188. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 189. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 190. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 191. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 192. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 193. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 194. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 195. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 196. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 197. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 198. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 199. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 200. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 201. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 202. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 203. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 204. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 205. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 206. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 207. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 208. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 209. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 210. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 211. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 212. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 213. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 214. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 215. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 216. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 217. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 218. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 219. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 220. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 221. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 222. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 223. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 224. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 225. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 226. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 227. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 228. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 229. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 230. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 231. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 236. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 237. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 238. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 239. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
TABLE 240. GLOBAL HEAD & NECK CANCER DRUGS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 241. GLOBAL HEAD & NECK CANCER DRUGS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 242. GLOBAL HEAD & NECK CANCER DRUGS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 243. GLOBAL HEAD & NECK CANCER DRUGS MARKET RANKING, BY KEY PLAYER, 2021
TABLE 244. GLOBAL HEAD & NECK CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 245. GLOBAL HEAD & NECK CANCER DRUGS MARKET MERGER & ACQUISITION
TABLE 246. GLOBAL HEAD & NECK CANCER DRUGS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 247. GLOBAL HEAD & NECK CANCER DRUGS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 248. GLOBAL HEAD & NECK CANCER DRUGS MARKET INVESTMENT & FUNDING
TABLE 249. GLOBAL HEAD & NECK CANCER DRUGS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 250. GLOBAL HEAD & NECK CANCER DRUGS MARKET: LICENSE & PRICING

Companies Mentioned

  • AbbVie
  • Amgen Inc.
  • AstraZeneca Plc.
  • BeiGene
  • Biocon
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company Limited
  • F. Hoffmann-La Roche Ltd.
  • Fortress Biotech, Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Gilead Sciences
  • GlaxoSmithKline
  • Incyte Corp
  • Johnson & Johnson
  • Merck & Co., Inc.
  • NEC Corporation
  • North Carolina Biotechnology Center
  • Novartis
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited

Methodology

Loading
LOADING...